Pipeline And Commercial Insight: Insomnia - Future Of Innovative Orexin Drug Class In Doubt

Introduction

Introduction

The availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intensified competition for both existing and prospective players in the insomnia market. Following the discontinuation of three 5-HT antagonists in late-stage development over 20092010, orexin receptor antagonists now represent the most innovative candidates in the insomnia pipeline.

Scope

*Analysis of insomnia epidemiology, drug recommendations, patient acquisition process and unmet medical needs.

*In depth analysis of historic (200509) and future (201019) seven major market prescription sales dynamics.

*Review of prescription sales data in the Rest of World (200509) and analysis of insomnia epidemiology in Brazil and China.

*Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and country-specific sales forecasts to 2019.

Highlights

In 2019, the value of the seven major insomnia market is forecast to reach $3.5 billion. While growth of the US market is set to be inhibited by further generic erosion from 2011 onwards, Japan will represent the key growth region over the next 10 years.

Sanofi-Aventis's dominance in the insomnia market is under threat due to patent challenges to Ambien CR and Datamonitor expects generic versions of this market leading brand to enter the US over the forecast period. In the absence of pipeline insomnia candidates, Sanofi-Aventis is not expected to regain its market leading status.

Three orexin receptor antagonists are currently under late stage clinical development by two Big Pharma players; GlaxoSmithKline and Merck. While safety observations raised in a Phase III trial of almorexant are of concern to developers, it has potential to become the most successful pipeline candidate.

Reasons to Purchase

*Quantify the current and future size of the insomnia market in the seven major pharmaceutical markets.

*Identify potential licensing opportunities based on product portfolios and anticipated market needs.

*Understand the country-specific impact of key events in the insomnia market during the forecast period 2010 to 2019.

For more information please visit :

http://www.aarkstore.com/reports/Pipeline-and-Commercial-Insight-Insomnia-Future-of-innovative-orexin-drug-class-in-doubt-52759.html

by: Aarkstore Enterprise

POST COMMENT

Herbal Remedies v/s Medicinal Drugs Useful Remedies For Reducing High Blood Pressure Take Good Sleep Pills For Your Body Information About Lyme Disease - The Six Most Important Facts Use These Remedies To Control Or Prevent High Blood Pressure Yeast Intolerance Symptoms: Things To Avoid Great Sleep Suggestions For How To Sleep Better Choose What Your Body Asks For Colon Health Problems - Is Your Health At Risk? Enjoy Peace Of Mind In Home Health Care Sacramento Choosing The Latex Foam Pillow Perfect For Comfy Sleep Somebody Plz Help Me I Really Want To Get Back With Him What is Green Smoke, Electronic Cigarette ?